386 related articles for article (PubMed ID: 30391013)
1. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
3. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X
J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer stroma: an update on therapeutic targeting strategies.
Hosein AN; Brekken RA; Maitra A
Nat Rev Gastroenterol Hepatol; 2020 Aug; 17(8):487-505. PubMed ID: 32393771
[TBL] [Abstract][Full Text] [Related]
5. Novel Therapeutics for Pancreatic Adenocarcinoma.
Lowery MA; O'Reilly EM
Hematol Oncol Clin North Am; 2015 Aug; 29(4):777-87. PubMed ID: 26226910
[TBL] [Abstract][Full Text] [Related]
6. Emerging Treatment Strategies in Pancreatic Cancer.
Trunk A; Miotke L; Nevala-Plagemann C; Verdaguer H; Macarulla T; Garrido-Laguna I
Pancreas; 2021 Jul; 50(6):773-787. PubMed ID: 34398070
[TBL] [Abstract][Full Text] [Related]
7. FAK and paxillin, two potential targets in pancreatic cancer.
Kanteti R; Batra SK; Lennon FE; Salgia R
Oncotarget; 2016 May; 7(21):31586-601. PubMed ID: 26980710
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
9. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
10. Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight.
Sato N; Kohi S; Hirata K; Goggins M
Cancer Sci; 2016 May; 107(5):569-75. PubMed ID: 26918382
[TBL] [Abstract][Full Text] [Related]
11. Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors.
Manuel ER; Chen J; D'Apuzzo M; Lampa MG; Kaltcheva TI; Thompson CB; Ludwig T; Chung V; Diamond DJ
Cancer Immunol Res; 2015 Sep; 3(9):1096-107. PubMed ID: 26134178
[TBL] [Abstract][Full Text] [Related]
12. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
13. New therapeutic targets in pancreatic cancer.
Lai E; Puzzoni M; Ziranu P; Pretta A; Impera V; Mariani S; Liscia N; Soro P; Musio F; Persano M; Donisi C; Tolu S; Balconi F; Pireddu A; Demurtas L; Pusceddu V; Camera S; Sclafani F; Scartozzi M
Cancer Treat Rev; 2019 Dec; 81():101926. PubMed ID: 31739115
[TBL] [Abstract][Full Text] [Related]
14. The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal.
Bijlsma MF; van Laarhoven HW
Cancer Metastasis Rev; 2015 Mar; 34(1):97-114. PubMed ID: 25566685
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
Christenson ES; Jaffee E; Azad NS
Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
[TBL] [Abstract][Full Text] [Related]
16. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
17. Emerging antibodies for the treatment of pancreatic cancer.
Andrikou K; Peterle C; Pipitone S; Salati M; Cascinu S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):39-51. PubMed ID: 28253833
[TBL] [Abstract][Full Text] [Related]
18. TGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma.
Alvarez MA; Freitas JP; Mazher Hussain S; Glazer ES
J Gastrointest Cancer; 2019 Jun; 50(2):207-213. PubMed ID: 30891677
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
20. Current and Emerging Therapies in Metastatic Pancreatic Cancer.
Manji GA; Olive KP; Saenger YM; Oberstein P
Clin Cancer Res; 2017 Apr; 23(7):1670-1678. PubMed ID: 28373365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
